Beta-Blockers Are the Primary Antihypertensive Class That Causes Fatigue
Beta-blockers are the antihypertensive medication class most clearly associated with fatigue, though the absolute risk is small—approximately 1 additional report of fatigue per 57 patients treated annually. 1
Understanding Beta-Blocker-Related Fatigue
Magnitude of Risk
The evidence from major clinical trials demonstrates that:
- Fatigue occurs in an additional 18 per 1,000 patients per year compared to placebo 2
- This represents a small but statistically significant increase
- Early-generation beta-blockers (like propranolol, atenolol) carry higher fatigue risk than late-generation agents (like carvedilol, nebivolol) 2
- Depression is NOT significantly increased with beta-blockers, contrary to common belief 2
Clinical Context and Management
The ACC/AHA Heart Failure Guidelines explicitly identify fatigue as one of four key adverse reactions requiring attention when initiating beta-blocker therapy 1. However, fatigue is multifactorial and is the hardest symptom to address with confidence—clinicians must rule out:
- Sleep apnea
- Overdiuresis (excessive diuretic use)
- Depression
- Other medical causes
Critical point: Even when fatigue occurs, beta-blockers should generally be continued in patients with heart failure, post-MI, or angina because the mortality benefits substantially outweigh this side effect 1.
Other Antihypertensive Classes and Fatigue
Central Alpha-2 Agonists
Central acting drugs (clonidine, methyldopa, guanfacine) cause significant CNS adverse effects including fatigue and are reserved as last-line agents 3, 4. Older central agents cause more fatigue than newer imidazoline receptor agents 5.
Diuretics
While not primarily associated with fatigue, diuretics can cause fatigue indirectly through:
- Volume depletion/overdiuresis 1
- Electrolyte abnormalities
- This is a management issue rather than a direct drug effect
Other Classes Have Minimal Fatigue Risk
- ACE inhibitors and ARBs: No significant fatigue association 6
- Calcium channel blockers: No significant fatigue association 6
- Alpha-1 blockers: Associated with orthostatic hypotension but not specifically fatigue 3, 4
Practical Clinical Algorithm
When a hypertensive patient reports fatigue:
- Review current medications: Identify if beta-blockers or central agents are being used
- Assess for alternative causes:
- Screen for sleep apnea (snoring, daytime sleepiness)
- Check for overdiuresis (orthostatic vital signs, volume status)
- Evaluate for depression
- Review electrolytes (hypokalemia, hyponatremia)
- If beta-blocker is implicated:
- Do NOT discontinue if patient has heart failure, recent MI, or angina—mortality benefits are paramount 1
- Consider switching from early-generation (atenolol, metoprolol tartrate, propranolol) to late-generation agents (carvedilol, nebivolol) which have lower fatigue rates 2
- Reduce dose if clinically appropriate
- If central agent is implicated: Switch to first-line agents (ACEi, ARB, CCB, thiazide diuretic) 3, 4
Important Caveats
Beta-Blockers in Metabolic Syndrome
Beta-blockers (especially with thiazide diuretics) should be avoided in patients with metabolic syndrome or high diabetes risk due to dysmetabolic effects, not fatigue 6. Vasodilating beta-blockers (carvedilol, nebivolol) have less metabolic impact 6.
Sedentary Time
Recent evidence shows beta-blocker use and use of ≥3 antihypertensives are associated with 44-52% increased odds of high sedentary time in older adults 7, which may contribute to perceived fatigue and has independent adverse health consequences.
Patient-Reported Symptoms
A 2025 study found that 90% of hypertensive patients report at least one symptom (tiredness, dizziness, etc.) that is at least somewhat problematic, with 39% reporting symptoms as big or very big problems 8. Perceived medication-relatedness strongly predicts treatment dissatisfaction and nonadherence 8. This underscores the importance of actively eliciting and addressing fatigue complaints.
The bottom line: While beta-blockers cause a small absolute increase in fatigue risk, this should not prevent their use when clinically indicated for compelling indications (heart failure, post-MI, angina). For uncomplicated hypertension without these indications, first-line agents (ACEi, ARB, CCB, thiazide diuretics) are preferred and have minimal fatigue risk 3, 4.